Live Breaking News & Updates on Blueprint Medicines

Stay updated with breaking news from Blueprint medicines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Avidity Partners Management LP Decreases Stake in Blueprint Medicines Co. (NASDAQ:BPMC)

Avidity Partners Management LP lessened its stake in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 18.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 615,000 shares of the biotechnology company’s stock after selling 136,600 shares during the quarter. Blueprint Medicines accounts for approximately 2.1% of Avidity […] ....

United States , Piper Sandler , Ariel Hurley , Stifel Nicolaus , Michael Landsittel , Blueprint Medicines Co , Jump Financial , Securities Exchange Commission , Compass Wealth Management , Headlands Technologies , Blueprint Medicines Corporation , Blueprint Medicines Company Profile , Associates Corp , Avidity Partners Management , Blueprint Medicines , Free Report , Partners Management , Wealth Management , Management Fondsmaeglerselskab , Get Free Report , Exchange Commission , Medicines Corporation , Visit Holdingschannel , Blueprint Medicines Daily ,

Avidity Partners Management LP Has $56.73 Million Stake in Blueprint Medicines Co. (NASDAQ:BPMC)

Avidity Partners Management LP decreased its position in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 18.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 615,000 shares of the biotechnology company’s stock after selling 136,600 shares during the quarter. Blueprint Medicines comprises […] ....

United States , Leerink Partnrs , Ariel Hurley , L Becker Hewes , Associates Corp , Exchange Commission , Blueprint Medicines Corporation , Goldman Sachs Group , Securities Exchange Commission , Headlands Technologies , Jump Financial , Blueprint Medicines Co , Compass Wealth Management , Avidity Partners Management , Blueprint Medicines , Free Report , Partners Management , Wealth Management , Management Fondsmaeglerselskab , Get Free Report , Medicines Corporation , Visit Holdingschannel , Blueprint Medicines Daily ,

Eagle Asset Management Inc. Boosts Stake in Blueprint Medicines Co. (NASDAQ:BPMC)

Eagle Asset Management Inc. raised its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 231,396 shares of the biotechnology company’s stock after acquiring an additional 22,279 […] ....

United States , Ariel Hurley , Stifel Nicolaus , Piper Sandler , Jeffreyw Albers , Axiom Investors , Exchange Commission , Eagle Asset Management Inc , Brown Advisory Inc , Needham Company , Blueprint Medicines Corporation , Blueprint Medicines Co , Norges Bank , Eagle Asset Management , Blueprint Medicines , Free Report , Asset Management , Management Fondsmaeglerselskab , Brown Advisory , Get Free Report , Director Jeffrey , Medicines Corporation , Visit Holdingschannel , Blueprint Medicines Daily ,

Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer

Trastuzumab deruxtecan improved PFS vs chemotherapy in pretreated, HR-positive, HER2-low or -ultralow metastatic breast cancer. ....

United States , New Haven , Daiichi Sankyo , Daichii Sankyo , Roche Genentech , Ian Krop , Bristol Myers Squibb , European Society Of Breast Cancer Specialists , Guardant Health , Clinical Trials Office , Clinical Sciences At Yale Cancer Center , Boehringer Ingelheim , Gilead Sciences , Foundation Medicine , Clinical Sciences , Yale Cancer Center , European Society , Breast Cancer Specialists , Ellipses Pharma , Blueprint Medicines , Exact Sciences , Hengrui Therapeutics ,

Blueprint Medicines Co. (NASDAQ:BPMC) Receives $103.94 Average Target Price from Analysts

Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seventeen research firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, nine have given a buy recommendation and […] ....

United States , Kate Haviland , Piper Sandler , Christopherk Murray , Securities Exchange Commission , Blueprint Medicines Corporation , Blueprint Medicines Co , Headlands Technologies , Covestor Ltd , Associates Corp , Compass Wealth Management , Blueprint Medicines , Get Free Report , Marketbeat Ratings , Exchange Commission , Wealth Management , Get Free , Medicines Corporation , Blueprint Medicines Daily ,